What is a stock summary page? Click here for an overview.
Business Description
Whitehawk Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US00032Q1040
Compare
Compare
Traded in other countries / regions
AADI.USA3350.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2021-08-27Description
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 56.71 | |||||
| Equity-to-Asset | 0.75 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -3.2 | |||||
| Beneish M-Score | -2.49 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.4 | |||||
| 3-Year EBITDA Growth Rate | -167.4 | |||||
| 3-Year EPS without NRI Growth Rate | -144.5 | |||||
| 3-Year FCF Growth Rate | -57.1 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 18.29 | |||||
| 9-Day RSI | 25.21 | |||||
| 14-Day RSI | 29.01 | |||||
| 3-1 Month Momentum % | -18.86 | |||||
| 6-1 Month Momentum % | 24.27 | |||||
| 12-1 Month Momentum % | 9.4 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.59 | |||||
| Quick Ratio | 3.28 | |||||
| Cash Ratio | 2.77 | |||||
| Days Inventory | 705.86 | |||||
| Days Sales Outstanding | 80.87 | |||||
| Days Payable | 357.06 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.6 | |||||
| Shareholder Yield % | 0.46 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 88.36 | |||||
| Operating Margin % | -249.47 | |||||
| Net Margin % | -245.13 | |||||
| FCF Margin % | -235.55 | |||||
| ROE % | -80.46 | |||||
| ROA % | -63.55 | |||||
| ROIC % | -633.55 | |||||
| 3-Year ROIIC % | -5094.16 | |||||
| ROC (Joel Greenblatt) % | -928.33 | |||||
| ROCE % | -79.46 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 4.32 | |||||
| PS Ratio | 1.75 | |||||
| PB Ratio | 0.8 | |||||
| Price-to-Tangible-Book | 0.8 | |||||
| EV-to-EBIT | -0.57 | |||||
| EV-to-EBITDA | -0.57 | |||||
| EV-to-Revenue | 1.39 | |||||
| EV-to-Forward-Revenue | 0.49 | |||||
| EV-to-FCF | -0.74 | |||||
| Price-to-GF-Value | 0.29 | |||||
| Price-to-Net-Current-Asset-Value | 0.97 | |||||
| Price-to-Net-Cash | 1.43 | |||||
| Earnings Yield (Greenblatt) % | -175.44 | |||||
| FCF Yield % | -77.77 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:WHWK
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Whitehawk Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 25.983 | ||
| EPS (TTM) ($) | -2.35 | ||
| Beta | 0.29 | ||
| 3-Year Sharpe Ratio | -0.68 | ||
| 3-Year Sortino Ratio | -0.8 | ||
| Volatility % | 65.1 | ||
| 14-Day RSI | 29.01 | ||
| 14-Day ATR ($) | 0.154756 | ||
| 20-Day SMA ($) | 2.00525 | ||
| 12-1 Month Momentum % | 9.4 | ||
| 52-Week Range ($) | 1.21 - 3.812 | ||
| Shares Outstanding (Mil) | 46.29 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Whitehawk Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Whitehawk Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Whitehawk Therapeutics Inc Frequently Asked Questions
What is Whitehawk Therapeutics Inc(WHWK)'s stock price today?
The current price of WHWK is $1.70. The 52 week high of WHWK is $3.81 and 52 week low is $1.21.
When is next earnings date of Whitehawk Therapeutics Inc(WHWK)?
The next earnings date of Whitehawk Therapeutics Inc(WHWK) is 2025-05-08 Est..
Does Whitehawk Therapeutics Inc(WHWK) pay dividends? If so, how much?
Whitehawk Therapeutics Inc(WHWK) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers